MK0462 in Treatment of Migraine With Recurrence (MK0462-022)
Status:
Completed
Trial end date:
1996-07-01
Target enrollment:
Participant gender:
Summary
A study to evaluate rizatriptan/MK0462 (5 and 10 mg) for the treatment of acute migraine
attack and treatment of up to two headache recurrences compared to placebo.
The long term extension study which pools patients from MK0462-022, -025, and -029 is
described in NCT01286207.